What happened with PLSE stock today?

Pulse Biosciences announced it will present at the 44th J.P. Morgan Healthcare Conference on January 14, 2026. This is a visibility catalyst for a small-cap medtech name. As a reference, PLSE stock is quoted at $14.15, within a 52‑week range of $12.56 to $25.00. Traders may position ahead of updates.

What should investors watch for at the J.P. Morgan Healthcare Conference?

Focus on nanosecond PFA updates for atrial fibrillation and soft‑tissue ablation, regulatory timelines, and early commercialization plans. Listen for capital runway details and any partnership interest. Clear milestones and timing can influence sentiment and trading interest in PLSE stock after the investor presentation.

Is PLSE stock risky going into the event?

Yes. The company has minimal revenue and negative earnings, which raises execution risk. Liquidity appears strong and debt is low, but valuation screens rich. Event outcomes can swing sentiment quickly. Consider position sizing, stop-loss levels, and reassessing after the presentation before making follow-on decisions.

What technical levels matter most for PLSE stock now?

Key levels include the intraday high $14.75 and low $14.03, the Bollinger upper band near $15.30, the 50‑day average at $15.03, and the 200‑day at $16.04. ATR near 0.73 implies moderate daily swings. A sustained close above $15.30 would strengthen the near-term case.

Global Market Insights

PLSE Stock Today: December 29 – JPM Healthcare Conference Slot Announced

ByHuzaifa Zahoor December 30, 2025December 30, 2025

PLSE stock is in focus after Pulse Biosciences said it will present at the 44th J.P. Morgan Healthcare Conference on January 14, 2026. We view this as a visibility catalyst that could spark interest in small-cap medtech. As a reference point, PLSE stock is quoted at $14.15 with a 52‑week range of $12.56 to $25.00 and a market cap near $959 million. Investors will watch for updates on nanosecond pulsed-field ablation programs for atrial fibrillation and soft-tissue ablation, plus any commercialization plans and timelines.